It has shown significant efficacy in patients with various advanced solid tumors who have previously received multiple lines of systemic anti-tumor therapy, especially in HER2-expressing breast cancer, and has entered the Phase III clinical stage. This evidence concerns the gene ERBB2 and neoplasm.